About Haemonetics
Haemonetics is a company based in Braintree (United States) founded in 1971. The company has 3,020 employees as of March 31, 2024. Haemonetics has completed 9 acquisitions, including Arryx, Attune Medical and Cardival Medical. Haemonetics offers products and services including Plasma Collection Systems, BloodTrack Software, and SafeTrace Tx. Haemonetics operates in a competitive market with competitors including VISIE, Vetex Medical, MediSieve, Sisu Global Health and Immutrix Therapeutics, among others.
- Headquarter Braintree, United States
- Employees 3020 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Haemonetics Corporation
-
Annual Revenue
$1.36 B (USD)3.95as on Mar 31, 2025
-
Net Profit
$167.68 M (USD)42.64as on Mar 31, 2025
-
EBITDA
$337.93 M (USD)10.67as on Mar 31, 2025
-
Latest Funding Round
$3.8 M (USD), Grant
Sep 15, 2021
- Investors
-
Employee Count
3020
as on Mar 31, 2024
-
Investments & Acquisitions
Arryx
& 8 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Haemonetics
Haemonetics is a publicly listed company on the NYSE with ticker symbol HAE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Haemonetics
Haemonetics offers a comprehensive portfolio of products and services, including Plasma Collection Systems, BloodTrack Software, and SafeTrace Tx.
Tools for efficient plasma yield and donor experience enhancement.
Platform for blood inventory and safety management.
Software for blood center operations and traceability.
People of Haemonetics
Unlock access to complete
Unlock access to complete
Software Development Team
125 people
Senior Team
37 people
Leadership Team
36 people
Sales and Marketing
24 people
Product Management Team
22 people
Legal and Compliance
15 people
Finance and Accounting
15 people
Human Resources and Administration
13 people
Unlock access to complete
Funding Insights of Haemonetics
Investors in Haemonetics
Haemonetics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Haemonetics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Haemonetics
Haemonetics has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include Arryx, Attune Medical and Cardival Medical.
Investment portfolio details for Haemonetics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of device for coagulation diagnostic
|
Locked | Locked | 2017 | Locked | |
|
Patient temperature is modulated via esophageal cooling devices.
|
Locked | Locked | 2009 | Locked | |
|
Bioabsorbable implants and delivery systems for arteriotomy closure are developed.
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Haemonetics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Haemonetics
Detailed financials for Haemonetics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Haemonetics Comparisons
Peer comparison for Haemonetics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Haemonetics
Haemonetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as VISIE, Vetex Medical, MediSieve, Sisu Global Health and Immutrix Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of 3D intraoperative imaging technology for orthopedic, neuro, and spine surgery
|
|
| Locked | Locked | Locked |
Catheters for venous clot management and removal are developed.
|
|
| Locked | Locked | Locked |
Magnetic therapy is developed to treat blood-borne diseases.
|
|
| Locked | Locked | Locked |
Intraoperative autotransfusion devices are developed and provided.
|
|
| Locked | Locked | Locked |
Blood cleansing treatment device
|
Detailed competitors of Haemonetics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Haemonetics
Complete news archive for Haemonetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Haemonetics
Haemonetics was founded in 1971 and raised its 1st funding round 41 years after it was founded.
Haemonetics is headquartered in Braintree, United States. It is registered at Braintree, Massachusetts, United States.
Chris Simon is the current CEO of Haemonetics.
As of Mar 31, 2024, the latest employee count at Haemonetics is 3,020.
Annual revenue of Haemonetics is $1.36B as on Mar 31, 2025.
Haemonetics was founded in 1971 and is based in Braintree, United States. Operations focus on the hematology sector within the medical industry, where products and solutions are developed for blood management and related procedures. Offerings include SafeTrace for transfusion tracking in blood banks, Persona as a plasma collection system integrated with the NexSys PCS platform, and VASCADE for arterial and venous closure to limit risks in interventions.
Haemonetics's top competitors include VISIE, Vetex Medical and Sisu Global Health.
Haemonetics offers Plasma Collection Systems, BloodTrack Software, and SafeTrace Tx.
Yes, Haemonetics is publicly traded on NYSE under the ticker symbol HAE.
Haemonetics has made 9 acquisitions, including Arryx, Attune Medical, and Cardival Medical.
Haemonetics has 1 investor. Key investors include HHS.
The ticker symbol of Haemonetics is HAE on NYSE.